Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...

The NFL has announced its International Player Pathway (IPP) program Class of 2026, featuring 13 athletes representing 10 nations around the world. Established in 2017, the IPP program identifies ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

The plausible mechanism pathway “could accelerate gene therapy/editing development,” analysts at William Blair said Thursday, while adding that additional clarity is needed. Individualized therapies ...

Pathway will retain its brand and operate independently as Clearlake’s investment solutions business Pathway’s leadership team will remain intact The company was founded in 1991 Clearlake Capital ...

Mike Darnay is a digital producer and photojournalist at CBS Pittsburgh. Mike has also written and produced content for Vox Media and the Mon Valley Independent. He often covers overnight breaking ...

Novartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta.

BYU-Pathway Worldwide students in Lagos, Nigeria gather in March 2024. Enrollment in Nigeria surged from 6,603 students in 2023 to 11,724 in 2024. With higher education experiencing unprecedented ...

Health tech company Doximity bought Pathway Medical to bulk up its healthcare artificial intelligence capabilities as it looks to offer more free AI tools to doctors. The transaction closed July 29 ...

Researchers analyzed BTH definition, frequency, and severity across phase 3 clinical trials with terminal complement inhibitors (ravulizumab and crovalimab) and upstream complement inhibitors ...

Gefurulimab showed significant improvements in MG-ADL scores in the phase 3 PREVAIL study for anti-AChR antibody-positive gMG patients. The treatment was well tolerated, with a safety profile ...